Closed · HT942524GBMRPHDA · CFDA 12.420 · Discretionary

DOD Glioblastoma, Hypothesis Development Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
November 20, 2024
Close date
13
Expected awards

The verdict

DOD Glioblastoma, Hypothesis Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 13 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
13
expected awards
12.420
CFDA program

Archived opportunity record

DOD Glioblastoma, Hypothesis Development Award is closed (last close November 20, 2024). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed November 20, 2024

Posted Sep 16 Closes Nov 20

Est. Total Funding

$4,640,000

Expected Awards

13

Instrument

Grant

Description

The FY24 GBMRP Hypothesis Development Award supports the exploration of highly innovative, untested, exploratory, high-risk/potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more of the FY24 GBMRP Hypothesis Development Award Focus Areas.This award is designed to provide investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation. Results of studies conducted through this award may provide the scientific premise upon which a new hypothesis can be based or initial proof-of-principle of an innovative hypothesis, laying the groundwork for future glioblastoma-focused research projects.The GBMRP encourages applications from early-career investigators and applications that include meaningful and productive collaborations between investigators. PIs with little to no previous glioblastoma experience are encouraged to collaborate with experienced glioblastoma researchers and/or clinicians.Key Aspects of the Hypothesis Development Award:Presentation of preliminary data is inconsistent with the intent of this award mechanism and is therefore strongly discouraged. However, proposals should be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.Innovation: It is the responsibility of the Principal Investigators (PIs) to clearly and explicitly articulate how the proposed research project meets the exploratory intent of this mechanism and is innovative in the field of glioblastoma research.Impact: The PI(s) should articulate the short- and long-term impact of the proposed research on both the glioblastoma research field as well as the patient community. The anticipated impact must be significant and move beyond an incremental advancement.Partnering Principal Investigator Option: The FY24 GBMRP Hypothesis Development Award includes an option for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as the Partnering PI. This funding opportunity allows one Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

Catch-all / unrestricted eligibility mark · HT942524GBMRPHDA

Grants.gov marks DOD Glioblastoma, Hypothesis Development Award with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

What to do next

DOD Glioblastoma, Hypothesis Development Award is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants